公开(公告)号：US09592293B2

公开(公告)日：2017-03-14

申请号：US14101145

申请日：2013-12-09

Applicant: AbbVie Inc.

Inventor： Chengbin Wu ,  Richard W. Dixon ,  Jonathan P. Belk ,  Maria A. Argiriadi ,  Hua Ying ,  Carolyn A. Cuff ,  Terry L. Melim ,  Shankar Kumar ,  Paul R. Hinton ,  Yan Chen

IPC: A61K39/395 ,  A61K45/06 ,  C07K14/47 ,  C07K16/24 ,  A61K38/00

CPC classification number: A61K45/06 ,  A61K38/00 ,  A61K39/3955 ,  C07K14/47 ,  C07K16/244 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  Y02A50/385 ,  Y02A50/401 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/463 ,  Y02A50/473 ,  Y02A50/478 ,  Y02A50/481

Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.

Abstract translation: 本发明包括IL-13结合蛋白。 具体地，本发明涉及作为嵌合，CDR移植和人源化抗体的抗体。 优选的抗体对hIL-13具有高亲和力，并在体外和体内中和hIL-13活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-13和抑制hIL-13活性，例如在患有hIL-13活性有害的病症的人类受试者中。

公开(公告)号：US20190008966A1

公开(公告)日：2019-01-10

申请号：US16113027

申请日：2018-08-27

Applicant: AbbVie Inc.

Inventor： Chengbin Wu ,  Richard W. Dixon ,  Jonathan P. Belk ,  Hua Ying ,  Maria A. Argiriadi ,  Carolyn A. Cuff ,  Paul R. Hinton ,  Shankar Kumar ,  Terry L. Melim ,  Yan Chen

IPC: A61K45/06 ,  C07K14/47 ,  C07K16/24 ,  A61K39/395 ,  A61K38/00

Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.

公开(公告)号：US20140178332A1

公开(公告)日：2014-06-26

申请号：US14154076

申请日：2014-01-13

Applicant: ABBVIE INC.

Inventor： Susan E. Lacy ,  Emma Fung ,  Jonathan P. Belk ,  Richard W. Dixon ,  Michael Roguska ,  Paul R. Hinton ,  Shankar Kumar

IPC: C07K16/24 ,  A61K39/395 ,  G01N33/68 ,  A61K45/06

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  C07K2317/24 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6869

Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

Abstract translation: 本发明包括IL-12p40结合蛋白，特别是结合人白细胞介素-12（hIL-12）和/或人IL-23（hIL-23）的抗体。 具体地，本发明涉及作为嵌合，CDR移植和人源化抗体的抗体。 优选的抗体对hIL-12和/或hIL-23具有高亲和力，并在体外和体内中和h IL-12和/或hIL-23活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-12和/或hIL-23和用于抑制hIL-12和/或hIL-23活性，例如在患有hIL -12和/或hIL-23活性是有害的。

公开(公告)号：US11344621B2

公开(公告)日：2022-05-31

申请号：US16113027

申请日：2018-08-27

Applicant: AbbVie Inc.

Inventor： Chengbin Wu ,  Richard W. Dixon ,  Jonathan P. Belk ,  Hua Ying ,  Maria A. Argiriadi ,  Carolyn A. Cuff ,  Paul R. Hinton ,  Shankar Kumar ,  Terry L. Melim ,  Yan Chen

IPC: A61K39/395 ,  A61K45/06 ,  C07K14/47 ,  C07K16/24 ,  A61K38/00

Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.

公开(公告)号：US10086076B2

公开(公告)日：2018-10-02

申请号：US15457264

申请日：2017-03-13

Applicant: AbbVie Inc.

Inventor： Chengbin Wu ,  Richard W. Dixon ,  Jonathan P. Belk ,  Hua Ying ,  Maria A. Argiriadi ,  Carolyn A. Cuff ,  Paul R. Hinton ,  Shankar Kumar ,  Terry L. Melim ,  Yan Chen

IPC: A61K39/395 ,  A61K45/06 ,  C07K14/47 ,  C07K16/24 ,  A61K38/00

Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.